Robbie Woodman
Presidente presso Transine Therapeutics Ltd.
Posizioni attive di Robbie Woodman
Società | Posizione | Inizio | Fine |
---|---|---|---|
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - | - |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Presidente | - | - |
Panakes Partners SGR SpA
Panakes Partners SGR SpA Investment ManagersFinance Panakes Partners Sgr SpA (Panakes Partners) is a venture capital firm founded in 2015 by Alessio Beverina, Fabrizio Landi and Diana Sareceni. The firm is headquartered in Milan, Italy. | Investitore di Private Equity | 01/01/2021 | - |
Storia della carriera di Robbie Woodman
Precedenti posizioni note di Robbie Woodman
Società | Posizione | Inizio | Fine |
---|---|---|---|
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Investitore di Private Equity | 01/03/2018 | 01/09/2021 |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Corporate Officer/Principal | 01/11/2020 | 01/09/2021 |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Corporate Officer/Principal | - | - |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investitore di Private Equity | - | - |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Corporate Officer/Principal | - | - |
BIOMX INC. | Corporate Officer/Principal | - | - |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formazione di Robbie Woodman
University of Oxford | Graduate Degree |
University of Cambridge | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Regno Unito | 5 |
Italia | 2 |
Posizioni
Corporate Officer/Principal | 6 |
Private Equity Investor | 3 |
Graduate Degree | 2 |
Settori
Finance | 6 |
Health Technology | 5 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
BIOMX INC. | Health Technology |
Aziende private | 9 |
---|---|
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Health Technology |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Finance |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Health Technology |
Panakes Partners SGR SpA
Panakes Partners SGR SpA Investment ManagersFinance Panakes Partners Sgr SpA (Panakes Partners) is a venture capital firm founded in 2015 by Alessio Beverina, Fabrizio Landi and Diana Sareceni. The firm is headquartered in Milan, Italy. | Finance |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Finance |
Abintus Bio, Inc.
Abintus Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Abintus Bio, Inc. operates as a preclinical stage gene therapy company. It provides immune cell reprogramming services. The company was founded by John Snyder, Nicholas A. Boyle, Douglas J. Jolly, Carlos Ibañez, Derek Ostertag, and Cory Bentley and is headquartered in Encinitas, CA. | Commercial Services |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Finance |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
- Borsa valori
- Insiders
- Robbie Woodman
- Esperienza